CytarabineDrug EvaluationRemission InductionAdolescentChildChild, PreschoolInfantFemaleThe toxicity of high dose cytosine arabinoside (Ara-C) in 23 leukemic children aged 1.5 years to 16 years 11 months was evaluated. The group included 11 children with acute lymphoblastic leukemia (ALL), nine with ...
High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in a... Background/AimAlthough induction chemotherapy comprising high-dose cytarabine (HiDAC) in combination with idarubicin and etoposide or ‘ICE’...
Objective In order to understand the adverse effects of the intensive consolidation induction chemotherapy with high dose cytarabine(HDAra-C) as the main drug to treat children with acute leukemia and the results of the comprehensive prevention measures to deal with such adverse effects.Methods 45 ch...
8, 9 R-MegaCHOEP, in turn, is not superior to R-CHOEP-14 and is associated with significantly more toxicity.10 Likewise, rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (R‐HCVAD)/rituximab, high-dose methotrexate (HD-Mtx), and cytarabine (R‐MA)...
Delivering a synergistic 5:1 molar ratio of cytarabine and daunorubicin, Vyxeos is the only nanoparticle formulation to date that has demonstrated superior overall survival when compared to the standard of care (i.e., 7-day continuous infusion of cytarabine with 3-day infusion of daunorubicin)25...
Bu/Cy + ATG + cytarabine GvHD prophylaxis: CSA, MMF, MTX (± ATG)MRDMedian CD3 dose: 5.51 × 107/kgPreemptive DLI vs Therapeutic DLI1-y OS: 94% —— 1-y OS: 27%6% —— 9% 24Prospective, nonrandomized phase 2 trialAML (n = 14) ...
“It looks like the addition of venetoclax to that background of low-intensity chemotherapy dramatically increases the response rate,” said Perl. “What is interesting about this abstract is not really the response rates—which you can do by adding more agents to low-dose cytarabine, but the ...
High-dose chemotherapy followed by autologous stem cell transplantation can improve the outcome of relapsed and refractory Hodgkin's disease (HD) patients. The objective of the trial was to determine the mobilizing potential of the DHAP salvage regimen (dexamethasone, cytarabine, cisplatin) for the ...
Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50(the dose lethal to 50% of the population) and the ED50(the dose therapeutically effective in 50% of the population)...
Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic of high-dose cytarabine therapy were absent. Since these results compare favorably with conventional induction regimens, its use in the primary treatment of adults and children with high...